Edwards Lifesciences Pre-Tax Profit Margin 2010-2022 | EW
Current and historical pre-tax profit margin for Edwards Lifesciences (EW) from 2010 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Edwards Lifesciences pre-tax profit margin for the three months ending December 31, 2022 was .
| Edwards Lifesciences Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2022-12-31 |
$5.38B |
$1.77B |
32.83% |
| 2022-09-30 |
$5.36B |
$1.68B |
31.39% |
| 2022-06-30 |
$5.36B |
$1.67B |
31.15% |
| 2022-03-31 |
$5.36B |
$1.75B |
32.65% |
| 2021-12-31 |
$5.23B |
$1.70B |
32.52% |
| 2021-09-30 |
$5.10B |
$1.68B |
33.01% |
| 2021-06-30 |
$4.93B |
$1.66B |
33.60% |
| 2021-03-31 |
$4.48B |
$0.94B |
21.03% |
| 2020-12-31 |
$4.39B |
$0.92B |
20.90% |
| 2020-09-30 |
$4.37B |
$0.88B |
20.07% |
| 2020-06-30 |
$4.32B |
$0.82B |
18.86% |
| 2020-03-31 |
$4.48B |
$1.25B |
27.97% |
| 2019-12-31 |
$4.35B |
$1.17B |
26.84% |
| 2019-09-30 |
$4.15B |
$0.85B |
20.45% |
| 2019-06-30 |
$3.97B |
$0.80B |
20.08% |
| 2019-03-31 |
$3.82B |
$0.78B |
20.30% |
| 2018-12-31 |
$3.72B |
$0.76B |
20.46% |
| 2018-09-30 |
$3.64B |
$1.09B |
29.93% |
| 2018-06-30 |
$3.55B |
$1.05B |
29.61% |
| 2018-03-31 |
$3.45B |
$1.01B |
29.18% |
| 2017-12-31 |
$3.44B |
$1.04B |
30.14% |
| 2017-09-30 |
$3.32B |
$0.91B |
27.50% |
| 2017-06-30 |
$3.23B |
$0.89B |
27.37% |
| 2017-03-31 |
$3.15B |
$0.85B |
26.92% |
| 2016-12-31 |
$2.96B |
$0.74B |
24.87% |
| 2016-09-30 |
$2.87B |
$0.70B |
24.56% |
| 2016-06-30 |
$2.74B |
$0.67B |
24.43% |
| 2016-03-31 |
$2.60B |
$0.64B |
24.72% |
| 2015-12-31 |
$2.49B |
$0.62B |
24.98% |
| 2015-09-30 |
$2.44B |
$0.59B |
24.13% |
| 2015-06-30 |
$2.43B |
$0.56B |
22.99% |
| 2015-03-31 |
$2.39B |
$1.23B |
51.46% |
| 2014-12-31 |
$2.32B |
$1.14B |
49.27% |
| 2014-09-30 |
$2.24B |
$1.11B |
49.60% |
| 2014-06-30 |
$2.13B |
$1.09B |
51.20% |
| 2014-03-31 |
$2.07B |
$0.40B |
19.22% |
| 2013-12-31 |
$2.05B |
$0.51B |
25.02% |
| 2013-09-30 |
$2.02B |
$0.53B |
26.29% |
| 2013-06-30 |
$1.97B |
$0.52B |
26.57% |
| 2013-03-31 |
$1.94B |
$0.49B |
25.45% |
| 2012-12-31 |
$1.90B |
$0.39B |
20.43% |
| 2012-09-30 |
$1.82B |
$0.34B |
18.58% |
| 2012-06-30 |
$1.78B |
$0.30B |
16.98% |
| 2012-03-31 |
$1.73B |
$0.29B |
16.50% |
| 2011-12-31 |
$1.68B |
$0.29B |
16.97% |
| 2011-09-30 |
$1.64B |
$0.29B |
17.43% |
| 2011-06-30 |
$1.58B |
$0.29B |
18.64% |
| 2011-03-31 |
$1.51B |
$0.29B |
18.99% |
| 2010-12-31 |
$1.45B |
$0.27B |
18.52% |
| 2010-09-30 |
$1.40B |
$0.26B |
18.54% |
| 2010-06-30 |
$1.38B |
$0.29B |
20.88% |
| 2010-03-31 |
$1.35B |
$0.29B |
21.11% |
| 2009-12-31 |
$1.32B |
$0.30B |
22.98% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$50.772B |
$5.382B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
